29 Papers
158 Citations
E. S. Kim is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Erlotinib & Medicine. The author has an hindex of 7, co-authored 22 publications.
Chat about Author
Papers
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-Tk inhibitor, for patients with recurrent non-small cell lung cancer
Alan Sandler,George R. Blumenschein,Ted Henderson,Ju Whei Lee,Mylene T. Truong,E. S. Kim,B. Mass,B. Garcia,David H. Johnson,Roy S. Herbst +9 more
TL;DR: The encouraging antitumor activity and favorable safety profile of AT support further development of this combination for advanced NSCLC.
43
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.
Roy S. Herbst,George R. Blumenschein,E. S. Kim,Ju-Whei Lee,Anne Tsao,Christine M. Alden,Stephen V. Liu,David J. Stewart,I. I. Wistuba,Waun Ki Hong +9 more
TL;DR: BATTLE is a phase II study to prospectively use biomarkers (BM) to guide treatment selection in patients with advanced non-small cell lung cancer (NSCLC) and shows promising results.
30
A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC)
C. H. Yang,Merrill S. Kies,Bonnie S. Glisson,B. J. Burke,Lawrence E. Ginsberg,Mylene T. Truong,M. M. Sugrue,Waun Ki Hong,Fadlo R. Khuri,E. S. Kim +9 more
TL;DR: An open-label phase II single-center study was conducted to determine the objective response rate of lonafarnib administered at 200 mg bid, enrolling patients who were incurable and who failed at least one platinum-containing regimen, but received no more than three prior regimens.
20
Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program
E. S. Kim,Roy S. Herbst,J. Jack Lee,George R. Blumenschein,Anne Tsao,I. I. Wistuba,Christine M. Alden,Supriya Gupta,David J. Stewart,Waun Ki Hong +9 more
TL;DR: BATTLE is one of the first studies in advanced lung cancer to prospectively utilize biomarker analysis of fresh biopsies to direct pt treatment, and is a step towards personalizing therapy in NSCLC.
18
Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN)
George R. Blumenschein,Charles Lu,Merrill S. Kies,Bonnie S. Glisson,Vassiliki A. Papadimitrakopoulou,Ralph Zinner,E. S. Kim,Ann M. Gillenwater,J. Chiao,Waun Ki Hong +9 more
TL;DR: SAHA at 400 mg qd appears to be well tolerated and has modest single agent activity in this small group of heavily pre-treated pts, and a dose intense schedule will be tested.
15